-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

802.O1.6 802. Chemical Biology and Experimental Therapeutics

Chemical Biology and Experimental Therapeutics Program: Oral and Poster Abstracts
Type: Oral
Monday, December 7, 2015: 4:30 PM-6:00 PM
W311EFGH, Level 3 (Orange County Convention Center)
Moderators:
Yana Pikman, MD, Dana-Farber Cancer Institute and Boston Children's Hospital and Cristina E. Tognon, PhD, Oregon Health and Science University

Disclosures:
No relevant conflicts of interest to declare.
4:30 PM

Stephen E Kurtz, PhD1*, Elie Traer, MD, PhD2, Jakki Martinez1*, Andrew Park1*, Jake Wagner1*, Ravi Pandya, PhD3*, William Bolosky, PhD3*, Brian J. Druker, MD2 and Jeffrey W. Tyner, PhD4

1Knight Cancer Institute, Oregon Health & Science University, Portland, OR
2Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
3Research, Microsoft, Redmond, WA
4Knight Cancer Institute, Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR

4:45 PM

Alyssa Carey, BS1*, Megan M Cleary, B.S., B.A.1*, David K Edwards V, B.A., B.S.2, Christopher A. Eide1,3*, Elie Traer, MD, PhD1, Shannon K. McWeeney, PhD4*, Jeffrey W. Tyner, PhD2, Grover C. Bagby, M.D.1,5, Brian J. Druker, MD1,3 and Anupriya Agarwal, PhD1

1Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
2Knight Cancer Institute, Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR
3Howard Hughes Medical Institute, Portland, OR
4Department of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR
5Portland VA Medical Center, Portland, OR

5:00 PM

Riikka Karjalalainen1*, Tea Pemovska1*, Muntasir Mamun Majumder1*, Bhagwan Yadav1*, Jing Tang1*, Mika Kontro2*, Bjørn Gjertsen, MD, PhD3, Alun Parsons1*, Minna Suvela1*, Kimmo Porkka2*, Tero Aittokallio1*, Olli Kallioniemi1*, Krister Wennerberg1*, Jonathan Knowles1* and Caroline Heckman1

1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
2Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
3Department of Clinical Science, University of Bergen, Bergen, Norway

5:15 PM

Laura Tornatore1*, Gary Acton2*, Nigel Adams3*, Elizabeth A Campbell4*, James Kelly5*, Richard M Szydlo, BSc, PhD6*, Mike Tarbit7*, Salina Bannoo1*, Daniel D'Andrea1*, Daria Capece1*, Annamaria Sandomenico8*, Julian Dyson1*, Antonio Leonardi9*, Christoph Driessen10*, Menotti Ruvo11*, Ishara Anees12*, Metod Oblak13*, Sheena Quaid14*, Magda J Al-Obaidi13*, Holger Auner1*, Reuben Benbenjamin15*, Richard S Kaczmarski16, Martin F Kaiser17*, Atul Mehta18, Heather E Oakervee19, Stephen A Schey20, Ashutosh Wechalekar21, Jane F. Apperley, MD22 and Guido Franzoso23*

1Imperial College London, London, United Kingdom
2Sunshine Clinical Ltd, Surrey, United Kingdom
3In2Phase Ltd, Welwyn Garden City, United Kingdom
4C&C Management Consulting Ltd, Exmouth, United Kingdom
5Alpha Preclinical Consultancy, Halifax, United Kingdom
6Centre for Haematology, Imperial College, London, United Kingdom
7Independent Consultant, Royston, United Kingdom
8University of Naples ‘‘Federico II, Naples, Italy
911Department of Molecular Medicine and Medical Biotechnologies, University of Naples ‘‘Federico II, Naples, Italy
10Department of Oncology/Hematology, Kantonsspital St. Gallen, St.Gallen, Swaziland
11Institute of Biostructures and Bioimages, National Research Council and CIRPeB, Naples, Italy
12Hillingdon Hospitals NHS Foundation Trust, London, United Kingdom
13West Middlesex University Hospital, London, United Kingdom
14Ealing Hospital, London, United Kingdom
15Kings College, London, United Kingdom
16Hillingdon Hospitals NHS Foundation Trust, london, United Kingdom
17Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
18Royal Free Hospital and University College Medical School, London, United Kingdom
19Barts Health NHS Trust, London, United Kingdom
20Department of Haemato-oncology, King's College London, London, United Kingdom
21University College London Medical School, National Amyloidosis Centre, London, United Kingdom
22Haematology Department, Hammersmith Hospital (Imperial College Healthcare NHS Trust), London, United Kingdom
23Centre for Cell Signalling and Inflammation, Imperial College London, London, United Kingdom

5:30 PM

Kirsten Canté-Barrett, PhD1, Joost CM Uitdehaag, PhD2*, Jessica GCAM Buijs-Gladdines1*, Wilco K Smits1*, Rogier C Buijsman, PhD2*, Guido JR Zaman, PhD2*, Rob Pieters, MD, PhD1,3 and Jules PP Meijerink, PhD1

1Department of Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
2Netherlands Translational Research Center B.V., Oss, Netherlands
3Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

5:45 PM

Lina Benajiba1*, Florence Wagner, PhD2*, Linda Ross, PhD1*, Ilene Galinsky, ANP3, Daniel J. DeAngelo, MD, PhD3, Jennifer Gale4*, Jen Pan, PhD4*, Yan-Lin Zhang, PhD4*, Joshua Sacher, PhD4*, Michel Weiwer, PhD4*, Richard M. Stone, MD3, Edward Holson, PhD2* and Kimberly Stegmaier, MD5

1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
2Stanley Center for Psychiatric Research, Broad Institute, Cambridge
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Broad Institute, Cambridge
5Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA

*signifies non-member of ASH